Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
:MIST
RESEARCH TOOLSreports
MIST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.63 - $2.75
Previous CloseN/A
Volume143.50K
Average Volume (3M)3.85M
Market Cap
$40.02M
Enterprise Value$111.02M
Total Cash (Recent Filing)-$26.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.67
Next Earnings
May 19, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding53,353,985
10 Day Avg. Volume5,686,266
30 Day Avg. Volume3,846,244
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)101.37
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.84
Forecast
1Y Price Target
$7.50Price Target Upside874.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityMilestone has a cash runway expected to last into mid-2026, providing financial stability until the anticipated launch.
Market OpportunityThe PSVT market remains significantly underserved, presenting a notable opportunity for CARDAMYST as a first-line, in-pocket treatment for acute PSVT episodes.
Sales InfrastructureMilestone’s efforts to build a cardiology-focused salesforce provide the infrastructure for a successful launch once approved.
Bears Say
Regulatory DelaysThe launch of CARDAMYST has been delayed due to a Complete Response Letter from the FDA, pushing the potential launch timeline by approximately one year.
Stock DowngradeThe stock rating for MIST was downgraded to Hold due to uncertainty surrounding the regulatory and commercial timing of etripamil.
Uncertainty In Approval TimelineThere is uncertainty about the timeline for NDA resubmission due to new concerns about FDA functionality.
---
Ownership Overview
0.80%
Insiders
0.03% Mutual Funds
25.35% Other Institutional Investors
73.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $0.63 and its highest was $2.75 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $40.02M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is May 19, 2025 which is in 37 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on Mar 13, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.156 by -$0.034.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -0.19.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 53,353,985 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.156. Following the earnings report the stock price went up 5.181%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
---
Milestone Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (874.03% Upside)
$7.50 (874.03% Upside)
Blogger Sentiment
Bullish
MIST Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 13.0%
Last 30 Days ▲ 13.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.51%
12-Months-Change
Fundamentals
Return on Equity
-277.55%
Trailing 12-Months
Asset Growth
0.36%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
---
MIST Stock 12 Month Forecast
Average Price Target
$7.50
▲(874.03% Upside)
Technical Analysis
BioCryst
―
VistaGen Therapeutics
―
Evolus
―
Xeris Pharmaceuticals
―
Arcutis Biotherapeutics
―
Best Analysts Covering MIST
1 Year
1 Year Success Rate
2/23 ratings generated profit
1 Year Average Return
-40.56%
reiterated a buy rating 11 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 8.70% of your transactions generating a profit, with an average return of -40.56% per trade.
---